Last reviewed · How we verify
NCT07507968
TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma
Phase 2 trial testing Durvalumab in Esophagogastric Adenocarcinoma in 101 participants. Not yet recruiting.
1 February 2030
Quick facts
| Lead sponsor | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 101 |
| Start date | 1 July 2026 |
| Primary completion | 1 February 2030 |
| Estimated completion | 1 February 2030 |
| Sites | 29 locations across Germany, Spain |
Drugs / interventions tested
- Durvalumab — full drug profile →
Conditions studied
- Esophagogastric Adenocarcinoma — all drugs for Esophagogastric Adenocarcinoma →
Sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest — full company profile →
Who can join
18 and older, any sex, with Esophagogastric Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial is designed to evaluate a total neoadjuvant approach using D-FLOT as the new standard backbone in patients with resectable esophagogastric adenocarcinoma. It addresses major limitations of current treatment paradigms, builds directly on the strong clinical signal from the MATTERHORN trial, and offers a rational, biologically sound framework for future therapy intensification and innovation. By moving systemic therapy entirely into the preoperative phase, we aim to: * Improve patient outcomes through better adherence and deeper response * Minimize postoperative therapy-related dropout * Create a platform for rational post-surgical drug testing and individualized treatment escalation The trial will provide pivotal evidence to guide the next generation of curative-intent treatment strategies for EGA.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07507968
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Durvalumab
Trials testing the same drug.
- NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting
- NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce · Phase 2 · recruiting
- NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
- NCT07459634 — A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC · Phase 2 · not yet recruiting
- NCT07288034 — Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatmen · Phase 2 · recruiting
Other recruiting trials for Esophagogastric Adenocarcinoma
Currently open trials in the same condition.
- NCT06731803 — Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Re · Phase 1, PHASE2 · recruiting
- NCT06623396 — A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer · Phase 1 · recruiting
Other Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest trials
Trials by the same sponsor.
- NCT07510724 — Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab · recruiting
- NCT07365930 — NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy · recruiting
- NCT06856837 — - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Misma · Phase 2 · recruiting
- NCT06731803 — Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Re · Phase 1, PHASE2 · recruiting
- NCT06123468 — Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma · Phase 1, PHASE2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07507968 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Last refreshed: 2 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07507968.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing